CN110903249B - Lopinavir prepared by one-pot method - Google Patents
Lopinavir prepared by one-pot method Download PDFInfo
- Publication number
- CN110903249B CN110903249B CN201911321242.XA CN201911321242A CN110903249B CN 110903249 B CN110903249 B CN 110903249B CN 201911321242 A CN201911321242 A CN 201911321242A CN 110903249 B CN110903249 B CN 110903249B
- Authority
- CN
- China
- Prior art keywords
- room temperature
- reaction
- solution
- lopinavir
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/10—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Lopinavir (I) is prepared by a one-pot method,
which is prepared by carrying out condensation reaction on 2, 6-dimethylphenoxy acetic acid, a carboxyl activating agent and a compound shown as a formula (III) in an organic solvent
Description
Technical Field
The invention relates to the technical field of medicines, and particularly relates to lopinavir prepared by a one-pot method.
Background
Lopinavir, chemical name: (2S) -N- [ (2R,4S,5S) -5- [ [2- (2, 6-dimethylphenoxy) acetyl ] amino ] -4-hydroxy-1, 6-diphenyl-hex-2-yl ] -3-methyl-2- (2-oxo-1, 3-diazacyclohex-1-yl) butanamide having the structure shown below:
lopinavir is an HIV-1 and HIV-2 protease inhibitor, can be combined with low-dose ritonavir to improve the pharmacokinetic properties of the lopinavir, and the lopinavir and low-dose ritonavir composite tablet is approved by the United states food and drug administration to be on the market in 2000, has reliable curative effect, less side effect and small food influence, is used as a first-line or second-line treatment medicament for resisting human immunodeficiency virus at present, and plays an important role in antiviral treatment of HIV patients who fail to initially treat drug resistance;
lopinavir has 4 chiral centers, the synthesis route reported in the literature is largely the same as or different from that reported in the prior art, mainly the parent nucleus structure of an amino alcohol compound is constructed, and then two side chains are respectively grafted to the parent nucleus structure and the parent nucleus structure, the prior synthesis route is mainly WO9721685A1 applied by the original Yapei company, and three synthesis methods are mainly disclosed in the patent:
in the method 1, expensive EDC is used as a condensing agent, and relatively expensive weak base 1-hydroxybenzotriazole is used, so that the method is simple and convenient in yield and post-treatment of operation, but is not suitable for industrial production in cost;
the method 2 comprises the following steps: reacting (2S) - (1-tetrahydropyrimidine-2-ketone) -3-methylbutyric acid with thionyl chloride, separating to obtain acyl chloride after the reaction is finished, and reacting with N- [ (1S,2S,4S) -4-amino-2-hydroxy-5-phenyl-1- (phenylmethyl) pentyl ] -2- (2, 6-dimethylphenoxy) acetamide to prepare lopinavir.
The acyl chloride prepared by the method 2 is unstable and is easy to decompose in water, and 10% of the acyl chloride is decomposed into (2S) - (1-tetrahydropyrimidine-2-ketone) -3-methylbutyric acid in about 10 minutes after being exposed in air (the humidity is about 75-80%), so that the method is not suitable for industrial production;
the method 3 comprises the following steps: (2S) - (1-tetrahydropyrimidin-2-one) -3-methylbutyric acid is reacted with thionyl chloride to form an acid chloride, which is reacted with an organic amine base (e.g., imidazole, pyridine, pyrrole and simple alkane derivatives thereof) to form an activated ester, which is then reacted with N- [ (1S,2S,4S) -4-amino-2-hydroxy-5-phenyl-1- (phenylmethyl) pentyl ] -2- (2, 6-dimethylphenoxy) acetamide to prepare lopinavir;
although the product quality and yield of the method 3 are acceptable, the step of activating ester reaction is added, the operation and the post-treatment are complicated, and the method is not suitable for industrial production in view of cost;
in conclusion, the development of a preparation method of lopinavir, an anti-HIV drug, is a technical problem to be solved urgently by technical personnel.
Disclosure of Invention
One of the objectives of the present invention is to provide a preparation method of lopinavir suitable for industrial production, so as to solve at least one technical problem in the prior art.
In order to realize the purpose of the invention, the invention provides the following technical scheme:
novel method for preparing lopinavir (I)
in some embodiments, the condensation reaction of the compound of formula (II) with the compound of formula (III) is performed at room temperature.
In some embodiments, the condensation reaction of the compound of formula (II) with the compound of formula (III) is carried out in the presence of a base.
In some embodiments, the base is triethylamine or pyridine.
The invention also provides a preparation method of the compound shown in the formula (II), which is prepared by carrying out condensation reaction on 2, 6-dimethylphenoxy acetic acid and a carboxyl activating agent in an organic solvent
In some embodiments, the carboxyl activating agent is CDI, DSC, DPhC, DMC, DCC.
In some embodiments, the organic solvent is ethyl acetate, DMF, acetonitrile, dichloromethane.
In some embodiments, the condensation reaction is performed under base catalysis.
In some embodiments, the base is triethylamine or pyridine.
In some embodiments, the condensation reaction is performed at room temperature.
In yet another aspect of the invention, there is provided a one-pot process for preparing lopinavir (I),
In some embodiments, the carboxyl activating agent is CDI, DSC, DPhC, DMC, DCC.
In some embodiments, the organic solvent is ethyl acetate, DMF, acetonitrile, dichloromethane.
In some embodiments, the condensation reaction is performed under base catalysis.
In some embodiments, the base is triethylamine or pyridine.
In some embodiments, the condensation reaction is performed at room temperature.
The invention has the beneficial effects that:
1. the lopinavir is prepared by the condensation reaction of a compound shown in a formula (II) and a compound shown in a formula (III), has few synthesis steps, and is prepared by taking 2, 6-dimethylphenoxy acetic acid and the compound shown in the formula (III) as starting materials and only needing two steps of reaction.
2. The condensation reaction is carried out at room temperature under mild conditions without heating or cooling;
3. the method does not need special chemical reagents, and is a solvent and a reagent which are commonly used in a laboratory;
4. the overall yield is higher than 85%, preferably higher than 90%, in some embodiments up to 96%.
5. The method can prepare lopinavir in one pot without separating intermediates, thereby greatly saving working procedures.
Therefore, the novel method for preparing lopinavir (I) is particularly suitable for industrial production.
Detailed Description
In order to make the technical solutions of the present invention better understood by those skilled in the art, the following further discloses some non-limiting examples to further explain the present invention in detail.
In the context of the present invention:
n, N' -Carbonyl Diimidazole (CDI)
N, N' -succinimidyl carbonate (DSC),
Diphenyl carbonate (DPhC),
Dimethyl carbonate, abbreviated as DMC,
N, N' -Dicyclohexylcarbodiimide (DCC).
2, 6-dimethylphenoxyacetic acid was purchased from Shanghai Xinda pharmaceutical Co., Ltd; the compound represented by the formula (III) is abbreviated as THP and is available from Racan chemical (Shanghai) Co.
In the present invention, room temperature means that the temperature of the reaction system is 10 to 35 ℃ and preferably 15 to 30 ℃.
Example 1
Examples 1 to 1
21.6g (0.12mol) of 2, 6-dimethylphenoxyacetic acid is dispersed in 150ml of dichloromethane to form a suspension, 17.8g of CDI (0.11mol) solid is added into the reaction liquid in batches at the normal temperature of 25 ℃, after the addition is finished, the reaction liquid is stirred for 2 hours at 25 ℃, 59.5g (0.1mol) of THP is added into the reaction liquid, and the stirring is continued for 8 hours at 25 ℃ until the reaction is finished. Quenching the reaction by 2g (0.02mol) of N, N-dimethyl-1, 3-propane diamine, continuing stirring for 2h at room temperature, washing the reaction solution by 100ml of 5% citric acid solution, 100ml of 5% sodium bicarbonate solution and 50ml of water for 3 times, and concentrating the organic phase under vacuum at the concentration temperature of not more than 50 ℃ to obtain 60.3g (96% yield) of lopinavir.
Examples 1 to 2
21.6g (0.12mol) of 2, 6-dimethylphenoxyacetic acid was dissolved in 60ml of DMF to prepare a solution, and 17.8g (0.11mol) of CDI was added in portions at 25 ℃ and stirred at room temperature for 1 hour. 59.5g (0.1mol) of THP was added to the reaction mixture at 25 ℃ and the mixture was stirred at room temperature for 8 hours until the reaction was complete. Quenching the reaction solution by using 2g (0.02mol) of N, N-dimethyl-1, 3-propane diamine, continuously stirring for 2h at room temperature, adding 200ml of 5% citric acid into the reaction solution, cooling to 5 ℃, stirring for 2h for crystallization, filtering, washing a filter cake by using a 5% citric acid solution, a 5% sodium bicarbonate solution and water, and drying the filter cake at a vacuum temperature of 50 ℃ to obtain 58.4g (93% yield) of lopinavir.
Examples 1 to 3
21.6g (0.12mol) of 2, 6-dimethylphenoxyacetic acid was dissolved in 250ml of EA to prepare a solution, and 17.8g (0.11mol) of CDI was added in portions at 25 ℃ and stirred at room temperature for 2 hours. 59.5g (0.1mol) of THP was added to the reaction mixture at 25 ℃ and the mixture was stirred at room temperature for 8 hours until the reaction was complete. The reaction solution was quenched with 2g (0.02mol) of N, N-dimethyl-1, 3-propanediamine, stirred at room temperature for 2h, washed with 100ml of 5% citric acid solution, 100ml of 5% sodium bicarbonate solution and 50ml of water in sequence for 3 times, and the organic phase was concentrated under vacuum at a concentration temperature of not more than 50 ℃ to obtain 60.9g (97% yield) of lopinavir.
Example 2
Example 2-1
21.6g (0.12mol) of 2, 6-dimethylphenoxyacetic acid was dissolved in 80ml of DMF and 8.8g of pyridine to prepare a solution, and 28.1g (0.11mol) of DSC was added in portions at 25 ℃ and stirred at room temperature for 1 hour. 59.5g (0.1mol) of THP and 10.1g (0.1mol) of triethylamine were added to the reaction mixture at 25 ℃ and the mixture was stirred at room temperature for 8 hours until the reaction was complete. Quenching the reaction solution by using 2g (0.02mol) of N, N-dimethyl-1, 3-propane diamine, continuously stirring for 2h at room temperature, adding 200ml of 5% citric acid into the reaction solution, cooling to 5 ℃, stirring for 2h for crystallization, filtering, washing a filter cake by using a 5% citric acid solution, a 5% sodium bicarbonate solution and water, and drying the filter cake at a vacuum temperature of 50 ℃ to obtain 56.5g (90% yield) of lopinavir.
Examples 2 to 2
21.6g (0.12mol) of 2, 6-dimethylphenoxyacetic acid was dissolved in 200ml of acetonitrile and 8.8g of pyridine to prepare a solution, and 28.1g (0.11mol) of DSC was added in portions at 25 ℃ and stirred at room temperature for 1 hour. 59.5g (0.1mol) of THP and 10.1g (0.1mol) of triethylamine were added to the reaction mixture at 25 ℃ and the mixture was stirred at room temperature for 8 hours until the reaction was complete. Quenching the reaction solution by using 2g (0.02mol) of N, N-dimethyl-1, 3-propane diamine, continuously stirring at room temperature for 2h, concentrating the reaction solution in vacuum, adding 150ml of EA to dissolve distillation residues, washing the EA solution by using a 5% citric acid solution, a 5% sodium bicarbonate solution and water, and evaporating the EA solution to dryness at the temperature of not more than 50 ℃ in vacuum to obtain 56.5g (90% yield) of lopinavir.
Example 3
Example 3-1
21.6g (0.12mol) of 2, 6-dimethylphenoxyacetic acid was dissolved in 80ml of DMF and 8.8g of pyridine to prepare a solution, and 38.7g (0.11mol) of DPhC was added in portions at 25 ℃ and stirred at room temperature for 1 hour. 59.5g (0.1mol) of THP and 10.1g (0.1mol) of triethylamine were added to the reaction mixture at 25 ℃ and the mixture was stirred at room temperature for 8 hours until the reaction was complete. Quenching the reaction solution by using 2g (0.02mol) of N, N-dimethyl-1, 3-propane diamine, continuously stirring for 2h at room temperature, adding 200ml of 5% citric acid into the reaction solution, cooling to 5 ℃, stirring for 2h for crystallization, filtering, washing a filter cake by using a 5% citric acid solution, a 5% sodium bicarbonate solution and water, and drying the filter cake at a vacuum temperature of 50 ℃ to obtain 54.6g (87% yield) of lopinavir.
Examples 3 to 2
21.6g (0.12mol) of 2, 6-dimethylphenoxyacetic acid was dissolved in 200ml of acetonitrile and 8.8g of pyridine to prepare a solution, 38.7g (0.11mol) of DPhC was added in portions at 25 ℃ and stirred at room temperature for 1 hour. 59.5g (0.1mol) of THP and 10.1g (0.1mol) of triethylamine were added to the reaction mixture at 25 ℃ and the mixture was stirred at room temperature for 8 hours until the reaction was complete. Quenching the reaction solution by using 2g (0.02mol) of N, N-dimethyl-1, 3-propane diamine, continuously stirring at room temperature for 2h, concentrating the reaction solution in vacuum, adding 150ml of EA to dissolve distillation residues, washing the EA solution by using a 5% citric acid solution, a 5% sodium bicarbonate solution and water, and evaporating the EA solution to dryness at the temperature of not more than 50 ℃ in vacuum to obtain 55.9g (89% yield) of lopinavir.
Example 4
Example 4-1
21.6g (0.12mol) of 2, 6-dimethylphenoxyacetic acid was dissolved in 80ml of DMF and 8.8g of pyridine to give a solution, and 42.2g (0.11mol) of DMC was added in portions at 25 ℃ and stirred at room temperature for 1 hour. 59.5g (0.1mol) of THP and 10.1g (0.1mol) of triethylamine were added to the reaction mixture at 25 ℃ and the mixture was stirred at room temperature for 8 hours until the reaction was complete. Quenching the reaction solution by using 2g (0.02mol) of N, N-dimethyl-1, 3-propane diamine, continuously stirring for 2h at room temperature, adding 200ml of 5% citric acid into the reaction solution, cooling to 5 ℃, stirring for 2h for crystallization, filtering, washing a filter cake by using a 5% citric acid solution, a 5% sodium bicarbonate solution and water, and drying the filter cake at a vacuum temperature of 50 ℃ to obtain 57.8g (92% yield) of lopinavir.
Example 4 to 2
21.6g (0.12mol) of 2, 6-dimethylphenoxyacetic acid was dissolved in 200ml of acetonitrile and 8.8g of pyridine to prepare a solution, and 42.2g (0.11mol) of DMC was added in portions at 25 ℃ and stirred at room temperature for 1 hour. 59.5g (0.1mol) of THP and 10.1g (0.1mol) of triethylamine were added to the reaction mixture at 25 ℃ and the mixture was stirred at room temperature for 8 hours until the reaction was complete. Quenching the reaction solution by using 2g (0.02mol) of N, N-dimethyl-1, 3-propane diamine, continuously stirring at room temperature for 2h, concentrating the reaction solution in vacuum, adding 150ml of EA to dissolve distillation residues, washing the EA solution by using a 5% citric acid solution, a 5% sodium bicarbonate solution and water, and evaporating the EA solution to dryness at the temperature of not more than 50 ℃ in vacuum to obtain 55.3g (88% yield) of lopinavir.
Example 5
Example 5-1
21.6g (0.12mol) of 2, 6-dimethylphenoxyacetic acid was dissolved in 60ml of DMF and 13.8g (0.12mol) of N-hydroxysuccinimide to prepare a solution, 22.7g (0.11mol) of DCC was added at once at-5 ℃, the reaction solution was warmed to room temperature and stirred at room temperature for 8 hours, and dicyclohexylurea as a by-product was removed by filtration. 59.5g (0.1mol) of THP and 10.1g (0.1mol) of triethylamine were added to the reaction mixture at 25 ℃ and the mixture was stirred at room temperature for 8 hours until the reaction was complete. The reaction solution was quenched with 2g (0.02mol) of N, N-dimethyl-1, 3-propanediamine, stirred at room temperature for 2h, 200ml of 5% citric acid was added to the reaction solution, cooled to 5 ℃, stirred for 2h for crystallization, filtered, the filter cake was washed with 5% citric acid solution, 5% sodium bicarbonate solution and water, the crude product was recrystallized from a mixed solution of isopropanol and hexane, and the crystals were dried at 50 ℃ under vacuum to obtain 51.5g (82% yield) of lopinavir.
Examples 5 and 2
21.6g (0.12mol) of 2, 6-dimethylphenoxyacetic acid was dissolved in 250ml of EA and 13.8g (0.12mol) of N-hydroxysuccinimide to prepare a solution, 22.7g (0.11mol) of DCC was added at once at-5 ℃, the reaction solution was warmed to room temperature and stirred at room temperature for 8 hours, and dicyclohexylurea as a by-product was removed by filtration. 59.5g (0.1mol) of THP and 10.1g (0.1mol) of triethylamine were added to the reaction mixture at 25 ℃ and the mixture was stirred at room temperature for 8 hours until the reaction was complete. The reaction solution was quenched with 2g (0.02mol) of N, N-dimethyl-1, 3-propanediamine, stirred at room temperature for 2h, washed with 100ml of 5% citric acid solution, 100ml of 5% sodium bicarbonate solution and 50ml of water in sequence for 3 times, and the organic phase was concentrated under vacuum at a concentration temperature of not more than 50 ℃ to obtain 60.3g (96% yield) of lopinavir.
The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (1)
1. Lopinavir (I) is prepared by a one-pot method,
The carboxyl activating agent is CDI, DSC, DPhC and DMC, and the structural formula is shown as follows:
the alkali used in the condensation reaction is triethylamine or pyridine; the organic solvent is ethyl acetate, DMF, acetonitrile and dichloromethane; the carboxyl activating agent is added in batches at 25 ℃, and the condensation reaction is carried out at room temperature.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911321242.XA CN110903249B (en) | 2019-12-20 | 2019-12-20 | Lopinavir prepared by one-pot method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911321242.XA CN110903249B (en) | 2019-12-20 | 2019-12-20 | Lopinavir prepared by one-pot method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110903249A CN110903249A (en) | 2020-03-24 |
| CN110903249B true CN110903249B (en) | 2021-05-25 |
Family
ID=69826735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911321242.XA Active CN110903249B (en) | 2019-12-20 | 2019-12-20 | Lopinavir prepared by one-pot method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110903249B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115108996A (en) * | 2022-07-27 | 2022-09-27 | 苏州健雄职业技术学院 | Novel lopinavir crystal form and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5905068A (en) * | 1996-09-24 | 1999-05-18 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| WO2008149228A1 (en) * | 2007-06-08 | 2008-12-11 | Aurobindo Pharma Limited | An improved process for the preparation of substantially pure (2s,3s,5s)-5-amino-2-n,n-dibenzylamino-3-hydroxy-1,6-diphenylhexane |
| CN106117148A (en) * | 2016-06-17 | 2016-11-16 | 厦门市蔚嘉化学科技有限公司 | A kind of preparation and purification technique of Lopinavir |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019186522A1 (en) * | 2018-03-30 | 2019-10-03 | Laurus Labs Limited | An improved process for preparation of lopinavir and its intermediates thereof |
| CN108218791A (en) * | 2018-04-04 | 2018-06-29 | 盐城迪赛诺制药有限公司 | A kind of method that one kettle way prepares Lopinavir |
-
2019
- 2019-12-20 CN CN201911321242.XA patent/CN110903249B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5905068A (en) * | 1996-09-24 | 1999-05-18 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| WO2008149228A1 (en) * | 2007-06-08 | 2008-12-11 | Aurobindo Pharma Limited | An improved process for the preparation of substantially pure (2s,3s,5s)-5-amino-2-n,n-dibenzylamino-3-hydroxy-1,6-diphenylhexane |
| CN106117148A (en) * | 2016-06-17 | 2016-11-16 | 厦门市蔚嘉化学科技有限公司 | A kind of preparation and purification technique of Lopinavir |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110903249A (en) | 2020-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI82189C (en) | Process for producing a stable modification of torasemide | |
| CN104761571A (en) | Synthesis method of edoxaban | |
| CN106966947A (en) | A kind of preparation method of vildagliptin | |
| CN112321613A (en) | Preparation method of idoxaban tosylate and isomer thereof | |
| CN110903249B (en) | Lopinavir prepared by one-pot method | |
| CN111018791B (en) | Novel method for preparing lopinavir | |
| CN105646446B (en) | A method of purifying Egelieting | |
| CN104513292A (en) | Preparation method of ramipril | |
| CN107089967A (en) | A kind of preparation method of R lipoic acids cholinester halide | |
| CN114437043B (en) | Preparation method of anti-new crown drug Nirmatrelvir | |
| CN108218808A (en) | A kind of preparation method of Ritonavir | |
| CN110981879B (en) | Method for preparing NS5A inhibitor-wipatasvir | |
| CN106749085A (en) | A kind of method for preparing Ritonavir | |
| KR101462850B1 (en) | Process for the preparation of highly pure entecavir monohydrate | |
| CN112661801A (en) | Nucleoside analogue and deuteron thereof, and preparation method and application thereof | |
| RU2794748C1 (en) | Synthesis of (1r,2s,5s)-n-[(1s)-1-cyano-2-[(3s)-2-oxopyrrrolidin-3-yl]ethyl]-3-[(2s)-3,3-dimethyl-2-[(2,2,2-trifluoroacetil)amino]butanoil]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-carboxamide | |
| CN111004255A (en) | Preparation method of cefcapene lactone compound or hydrochloride thereof | |
| CN108640912A (en) | A kind of industrially scalable preparation method of Pidotimod | |
| RU2794750C1 (en) | Method for producing (1r,2s,5s)-n-[(1s)-1-cyano-2-[(3s)-2-oxopyrrrolidin-3-yl]ethyl]-3-[(2s)-3,3- dimethyl-2-[(2,2,2-trifluoracetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-carboxamide | |
| JPS606958B2 (en) | Antibiotic purification method | |
| RU2794754C1 (en) | Method for producing (1r,2s,5s)-n-[(1s)-1-cyano-2-[(3s)-2-oxopyrrrolidin-3-yl]ethyl]-3-[(2s)-3,3- dimethyl-2-[(2,2,2-trifluoracetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-carboxamide | |
| RU2794755C1 (en) | Method for producing (1r,2s,5s)-n-[(1s)-1-cyano-2-[(3s)-2-oxopyrrrolidin-3-yl]ethyl]-3-[(2s)-3,3- dimethyl-2-[(2,2,2-trifluoracetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-carboxamide | |
| CN102863370A (en) | Novel synthetic method of antiepileptic drug levetiracetam | |
| CN113493467B (en) | Improved preparation method of penethamate hydroiodide | |
| CN115403515B (en) | Preparation method and application of pirenzenenaphthalene degradation impurity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |